Case Study
Revolutionizing Solid Tumor Treatment - KSQ Therapeutics Case Study
Abstract: Revolutionizing Solid Tumor Treatment - KSQ Therapeutics and MaxCyte Collaborate on Engineered eTILs® Immunotherapies
KSQ Therapeutics, a clinical-stage company developing engineered eTILs for solid tumors, leverages MaxCyte's advanced cell engineering platforms. KSQ utilizes MaxCyte's systems and expertise to engineer its lead KSQ-001EX eTIL program, currently in Phase 1 development. This collaborative partnership, initiated in 2019, aims to harness the power of CRISPRomics® and CRISPR2™ platforms to revolutionize the treatment of solid tumors through innovative cell therapies.
Case Study
Challenge
KSQ faced issues with editing efficiency, scalability, and consistency, needed flexibility for different donor volumes, and dealt with CDMO site shutdowns during COVID-19.
Solution
MaxCyte optimized GMP-ready scalable process, provided continuous support for consistent CRISPR Cas9 editing during scale-up, and assisted with CDMO site moves and regulatory updates
Impact
The collaboration resulted in a robust, GMP-compliant process from the get-go with superior gene editing outcomes (>90%) and minimized disruptions during the pandemic.
“Our partnership with Maxcyte has enabled KSQ to overcome key technical and operational challenges throughout development of our eTIL products. We are proud to continue our collaboration as we enter clinical manufacturing, delivering these important investigational therapies to patients.”
Thomas Leitch, Chief Technology Officer, KSQ Therapeutics, Inc.
Summary
- Collaboration: MaxCyte and KSQ Therapeutics have entered into a development and commercialization agreement.
- Technology: KSQ Therapeutics will leverage MaxCyte's Flow Electroporation® technology and ExPERT™ instruments.
- Application: This collaboration aims to advance KSQ's engineered tumor-infiltrating lymphocyte (eTIL™) programs.
- Technology Strength: MaxCyte's ExPERT instrument family represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cellular engineering.
